BRCA2 and ovarian serous adenocarcinoma: In an immunohistochemistry study including 48 patients with serous ovarian cancer and known germline BRCA mutation status (4 BRCA1-mutated, 8 BRCA2-mutated, 36 BRCA-wildtype), no association was found between germline BRCA mutation status and the infiltration of CD8+ T cells or Tregs or checkpoint expression (PD-L1 or LAG-3) [59].